[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,304,172
  • Shares Outstanding, K 133,809
  • Annual Sales, $ 3,714 M
  • Annual Income, $ 313,750 K
  • EBIT $ 1,000 M
  • EBITDA $ 1,055 M
  • 60-Month Beta 0.30
  • Price/Sales 7.94
  • Price/Cash Flow 78.80
  • Price/Book 21.77

Options Overview Details

View History
  • Implied Volatility 46.64% (-0.78%)
  • Historical Volatility 104.28%
  • IV Percentile 61%
  • IV Rank 57.44%
  • IV High 59.29% on 07/27/26
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 16) 6.97 (3.05%)
  • Put/Call Vol Ratio 0.25
  • Today's Volume 1,073
  • Volume Avg (30-Day) 1,942
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 38,959
  • Open Int (30-Day) 31,961
  • Expected Range 221.88 to 235.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $1.70
  • Number of Estimates 9
  • High Estimate $2.87
  • Low Estimate $1.27
  • Prior Year $1.84
  • Growth Rate Est. (year over year) -7.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
197.81 +14.74%
on 07/30/26
380.00 -40.27%
on 07/09/26
-85.82 (-27.44%)
since 07/02/26
3-Month
197.81 +14.74%
on 07/30/26
380.00 -40.27%
on 07/09/26
-74.14 (-24.62%)
since 05/05/26
52-Week
197.81 +14.74%
on 07/30/26
495.55 -54.20%
on 10/20/25
-191.95 (-45.82%)
since 08/05/25

Most Recent Stories

More News
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

LOS ANGELES , Aug. 4, 2026 /PRNewswire/ -- Schall, Brown & Schwartz  LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors...

ALNY : 226.94 (+3.63%)
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam”...

ALNY : 226.94 (+3.63%)
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam”...

ALNY : 226.94 (+3.63%)
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY ) investors concerning the Company’s...

ALNY : 226.94 (+3.63%)
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY ) on behalf of investors concerning...

ALNY : 226.94 (+3.63%)
Alnylam: Q2 Earnings Snapshot

Alnylam: Q2 Earnings Snapshot

ALNY : 226.94 (+3.63%)
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2...

ALNY : 226.94 (+3.63%)
Whether Alnylam's Guidance Can Justify Analysts Finally Turning Bullish After Years of Misses

Barchart Research What to Expect from ALNY Earnings ALNY Generated July 29, 2026 Current Price $286.62 EPS Estimate $$1.44 Consensus Rating Moderate Buy Average Move 6.38% Whether Alnylam's Guidance Can...

ALNY : 226.94 (+3.63%)
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday,...

ALNY : 226.94 (+3.63%)
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) − − Announces Completion of Enrollment in the...

ALNY : 226.94 (+3.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 230.21
2nd Resistance Point 226.40
1st Resistance Point 222.70
Last Price 226.94
1st Support Level 215.18
2nd Support Level 211.37
3rd Support Level 207.67

See More

52-Week High 495.55
Fibonacci 61.8% 381.81
Fibonacci 50% 346.68
Fibonacci 38.2% 311.55
Last Price 226.94
52-Week Low 197.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.